Table 2.

Pan-EBOV-vaccinated macaques following i.m. filovirus challenge

Challenge type and NHPa	Adverse events on days 1 to 28 after challengeb	Status
After challenge with 1,000 PFU of SUDV i.m.
Ctrl 5	Fever (days 5 and 7), depression (days 6 and 7), widespread rash (day 7), anorexia (days 5 to 7), viremia (days 5 and 7), thrombocytopenia (days 5 and 7), 4- to 5-fold increase in ALT and ALP, >5-fold increase in AST	Succumbed on day 8
Exp 7	No clinical signs	Survived
Exp 8	No clinical signs	Survived
Exp 9	No clinical signs	Survived
After back-challenge with 1,000 PFU of EBOV i.m.
Ctrl 6	Depression (days 6 and 7), anorexia (days 6 and 7), viremia (days 5 and 7), thrombocytopenia (days 5 and 7), 4- to 5-fold increase in ALP, >5-fold increase in ALT and AST	Succumbed on day 8
Exp 7	No clinical signs	Survived
Exp 8	No clinical signs	Survived
Exp 9	No clinical signs	Survived
After challenge with 1,000 PFU of EBOV i.m.
Ctrl 7	Fever (day 5), hypothermia (day 6), widespread rash (day 6), anorexia (days 5 and 6), viremia (days 3, 5, and 6), thrombocytopenia (days 5 and 6), 2- to 3-fold increase in ALP, >5-fold increase in ALT and AST	Succumbed on day 6
Exp 10	No clinical signs	Survived
Exp 11	No clinical signs	Survived
Exp 12	No clinical signs	Survived
After back-challenge with 1,000 PFU of SUDV i.m.
Ctrl 8	Fever (days 5 and 7), depression (day 7), widespread rash (day 7), anorexia (days 6 and 7), viremia (days 5 and 7), thrombocytopenia (days 5 and 7), 4- to 5-fold increase in ALT and ALP, >5-fold increase in AST	Succumbed on day 7
Exp 10	Fever (day 7), depression (days 7 to 9), mild rash (day 9), anorexia (days 8 and 9), viremia (days 5 and 7), >5-fold increase in ALT and AST	Succumbed on day 10c
Exp 11	No clinical signs	Survived
Exp 12	No clinical signs	Survived

^aCtrl, control animals; Exp, experimental animals.

^bALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AMY, amylase.

^cSuccumbed to MARV infection. PCR and antigen negative for SUDV at time of death.